Who owns Nutrafol now?

Unilever completed a full buyout of Nutrafol's remaining stake in early 2025, with co-founder Giorgos Tsetis exiting; a realized valuation of about $3.5 billion was reported by Inc. on October 27, 2025 (company-linked, unverified independently).

Is Nutrafol profitable?

No independent profitability figures are disclosed. Unilever says Nutrafol's turnover 'more than doubled' since the 2022 acquisition (2025-01-15) and CEO Cindy Gustafson claimed a 'path to $1 billion' in sales (2026-06-24), but these are company-sourced claims, not audited profit data.

Is Nutrafol laying off employees?

Crustdata tracked Nutrafol headcount at 386 in July 2026, down 3% year-over-year with a 'modest growth' score of 8/100, alongside a 27% quarter-over-quarter drop in web traffic, suggesting a growth plateau rather than mass layoffs.

Could AI replace Nutrafol's business?

AI can automate Nutrafol's quiz and personalization layer, but its moat rests on 20+ proprietary clinical studies, 4 formulation patents, and 3,000-4,500+ physician recommenders (per unilever.com, 2026-07-22), a distribution and trust network AI cannot easily replicate.

Who is Nutrafol's biggest competitor?

Vegamour is cited as Nutrafol's closest DTC rival in a March 2026 market report, while Hims & Hers poses a model-level threat via prescription finasteride telehealth, which dermatology commentary (2025-04-24) says has stronger independent clinical evidence than nutraceuticals.

Is Nutrafol being sued?

Yes. Multiple class actions filed since 2023 allege Nutrafol's 'clinically proven' and 'standardized' claims are misleading and that products may be misbranded drugs under the FDCA; Sephora was separately sued as a co-defendant over ingredient consistency in December 2025.

Consumer brands · subsidiary of Unilever · United States

Nutrafol

nutrafol.com ↗

Hair growth supplement brand, wholly owned by Unilever, sold via DTC, clinics, and retail.

Defensible for now

Assessed 23 July 2026 · Evidence as of 23 July 2026

Real protection, with named pressure against it.

On the recordSince 23 July 2026 · Checkable from H1 2027 · Every call on the record Checkpoint: Ruling or settlement in 'clinically proven' class-action and Sephora co-defendant suits

The call

Nutrafol holds a wide physician and retail network under Unilever ownership, but pending 'clinically proven' litigation and telehealth Rx alternatives sit directly against its core pitch.

Nutrafol sells vitamins and supplements for hair health directly to customers online and through stores like Sephora and Ulta, plus through doctors' recommendations. It is hard to copy because it has many repeat customers (80% buy again) and real studies backing up its claims, but Hims and Hers offers prescription hair-loss pills that have stronger scientific proof, and Unilever's deep pockets mean it could launch a competing product anytime. The biggest threat is ongoing lawsuits claiming Nutrafol falsely says its products are 'clinically proven,' which is exactly why people pay premium prices for it. If courts rule against the company or force it to change how it markets its products, customers may lose faith and switch to cheaper or prescription options instead.

Why

AI pressure: Hims & Hers AI-driven telehealth triage tools. AI symptom-checkers can route hair loss users straight to prescription finasteride, skipping supplement aisle entirely. Could AI do the core job? Unlikely.

Bigger players: Hims & Hers Health. Rx-based telehealth hair loss treatment has stronger independent clinical backing than nutraceuticals, pulling share from supplement brands. Could a giant copy it? Probably.

What protects it. Physician network of 3,000plus recommenders, 1M+ repeat customers, and Sephora/Ulta shelf space built over a decade.

What would change this call

Ruling or settlement in the 'clinically proven' class-action and Sephora co-defendant suits within 2-4 quarters. Would show whether Nutrafol must soften core marketing claims that justify its premium price.
Q4 2026 holiday revenue report reconciled against third-party web traffic and headcount trends. Would show whether Unilever's 'doubling revenue' claim matches or contradicts declining traffic and hiring.
Any statement from Unilever CEO Fernandez on Wellbeing division priority or Nutrafol resourcing. Would show whether Nutrafol stays a growth priority or gets deprioritized within Unilever's portfolio.

Key numbers

80% of DTC revenue from repeat buyers (2024-11-27)
Web traffic down 27% QoQ (2026-07-08)
Headcount down 3% YoY to 386 staff (2026-07-08)

Named risks

Active class actions alleging 'clinically proven' claims are misleading, could force marketing overhaul. Severity: high
Sephora co-defendant suit over ingredient consistency and undisclosed arsenic traces, Dec 2025. Severity: medium
Industry-wide FTC enforcement on supplement marketing claims (e.g., TruHeight settlement, 2026-02-13). Severity: medium
Plateauing growth: headcount down 3% YoY and web traffic down 27% QoQ as of mid-2026 despite $1B revenue claims. Severity: medium
Single case report linking Nutrafol use to liver injury could seed further litigation or FDA scrutiny. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Vegamour	contesting	Cited as Nutrafol's closest DTC hair-supplement/serum rival, market report 2026-03-15
Hims & Hers	gaining on	Rx finasteride telehealth model has stronger independent clinical evidence per dermatology commentary, 2025-04-24
P&G / L'Oreal / Kenvue	gaining on	Mass beauty incumbents run competing dermatologist-recommended OTC lines, no structural barrier to entry
Living Proof	contesting	Former Unilever hair-care brand cited as peer competitor per CB Insights profile, n.d.

Questions people ask

Who owns Nutrafol now?: Unilever completed a full buyout of Nutrafol's remaining stake in early 2025, with co-founder Giorgos Tsetis exiting; a realized valuation of about $3.5 billion was reported by Inc. on October 27, 2025 (company-linked, unverified independently).
Is Nutrafol profitable?: No independent profitability figures are disclosed. Unilever says Nutrafol's turnover 'more than doubled' since the 2022 acquisition (2025-01-15) and CEO Cindy Gustafson claimed a 'path to $1 billion' in sales (2026-06-24), but these are company-sourced claims, not audited profit data.
Is Nutrafol laying off employees?: Crustdata tracked Nutrafol headcount at 386 in July 2026, down 3% year-over-year with a 'modest growth' score of 8/100, alongside a 27% quarter-over-quarter drop in web traffic, suggesting a growth plateau rather than mass layoffs.
Could AI replace Nutrafol's business?: AI can automate Nutrafol's quiz and personalization layer, but its moat rests on 20+ proprietary clinical studies, 4 formulation patents, and 3,000-4,500+ physician recommenders (per unilever.com, 2026-07-22), a distribution and trust network AI cannot easily replicate.
Who is Nutrafol's biggest competitor?: Vegamour is cited as Nutrafol's closest DTC rival in a March 2026 market report, while Hims & Hers poses a model-level threat via prescription finasteride telehealth, which dermatology commentary (2025-04-24) says has stronger independent clinical evidence than nutraceuticals.
Is Nutrafol being sued?: Yes. Multiple class actions filed since 2023 allege Nutrafol's 'clinically proven' and 'standardized' claims are misleading and that products may be misbranded drugs under the FDCA; Sephora was separately sued as a co-defendant over ingredient consistency in December 2025.

Timeline

2026-07-21Launched next-generation Booster Nutraceuticals system with 7 new boosters
2026-07-08Crustdata reports headcount down 3% YoY, web traffic down 27% QoQ
2026-06-24CEO Gustafson says company on 'path to $1 billion' in annual sales
2026-05-11Named #1 dermatologist-recommended hair growth supplement by U.S. News, 3rd year
2026-03-30Launched myNutrafol app with tracking, consults, Real Growth Guarantee
2026-02-03Launched Nutrafol Men 50+ product line
2025-12-16Sephora sued as co-defendant over Nutrafol ingredient consistency claims
2025-05-07Class action alleges Nutrafol products are misbranded, not clinically proven
2025-01Cindy Gustafson becomes CEO, succeeding co-founder Giorgos Tsetis
2022-05-30Unilever acquires majority stake in Nutrafol at est. $1.2-1.25 billion valuation

Revision history

23 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Estée Lauder LVMH Moet Hennessy Louis Vuitton Chow Sang Sang Holdings International Limited